Nyrada, Inc.ASX: NYR

Presentation - Bell Potter Healthcare Conference 2026

· Issued by Nyrada, Inc. via ASX

Filed with ASX · · 13 pages · English

Summary by 6ix AI

The presentation highlights the ongoing Phase IIa trial for Xolatryp in cardiac reperfusion injury, with updates on patient recruitment and safety assessments. Nyrada emphasizes the significant market opportunity for Xolatryp, particularly in the context of STEMI heart attacks, where current treatment options are limited. The company outlines multiple near-term catalysts for development and expansion of their clinical programs across various therapeutic areas.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Bell Potter Healthcare Conference 2026 Building the Future of TRPC-targeted Therapies 19 November 2026 ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It...

Nyrada, Inc. on 6ix

Earlier from Nyrada

Later from Nyrada

All Nyrada news releases